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Clinical Impact of a Pharmaceutical Care 
Programme Developed in a Family Health Unit: 
Results of a Pharmacist-Physician Collaboration 
in the Treatment of Hypertensive Patients 
Impacto Clínico de um Programa de Acompanhamento 
Farmacoterapêutico Implementado numa Unidade de Saúde 
Familiar: Resultados de uma Colaboração entre Farmacêutico 
e Médico no Tratamento de Doentes Hipertensos
Abstract
Introduction: The positive impact of pharmacist-physician collaborative care has been reported in the 
international literature, although examples of this impact are limited in Portugal. We aim to underline the 
clinical added value for hypertensive patients that results from pharmacist-physician collaborations.
Methods: A community trial was conducted at a Portuguese family health unit for 19 months. The 
intervention group was randomly selected from the global records and members of the group received 
pharmaceutical care in addition to physician care. The comparison group received only physician care. 
Both groups were comparable at the beginning of the study. In the intervention group, we analysed the 
hypertensive patients to evaluate the impact of pharmacist-physician collaboration on the patients’ blood 
pressure levels. This evaluation was performed by comparing the obtained blood pressure levels with the 
levels at baseline and between the groups. 
Results: A total of 17 patients with hypertension were enrolled in the pharmaceutical care programme, 12 of 
whom were female. The mean age was 68.50±3.26 years and, on average, each patient consumed 6.06±0.93 
medicinal products. Thirteen patients were uncontrolled. Compared with the baseline, the intervention 
group achieved mean reductions of 28.85±5.90 mmHg (p < 0.0005) and 11.23±2.75 mmHg (p < 0.005) in their 
systolic and diastolic blood pressure, respectively. Considering the comparison group, improvements of 
18.63±6.44 mmHg (p = 0.011) in systolic blood pressure and 9.03±2.63 mmHg ( p < 0.005) in diastolic blood 
pressure were observed.
Conclusion: Pharmacist-physician collaborative care adds clinical value to the typical physician care 
provided to hypertensive patients within the context of a Portuguese family health unit. 
Keywords: Blood Pressure; Family Health; Hypertension; Interprofessional Relations; Pharmaceutical 
Services; Pharmacists; Physicians; Portugal; Treatment Outcome 
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Resumo
Introdução: O impacto positivo da colaboração entre farmacêutico-médico para a saúde do doente está 
bem documentado na literatura internacional. Em Portugal, os exemplos de colaboração são limitados. Com 
este trabalho pretendemos sublinhar a mais-valia clínica da colaboração farmacêutico-médico em doentes 
hipertensos.
Métodos: Ensaio comunitário desenvolvido numa unidade de saúde familiar portuguesa, durante 19 meses. 
O grupo de intervenção, selecionado aleatoriamente do ficheiro global, foi submetido a acompanhamento 
farmacoterapêutico pelo farmacêutico. O grupo de comparação recebeu apenas os cuidados médicos 
habituais. Ambos os grupos eram comparáveis à partida. Analisámos os doentes hipertensos para avaliar 
o impacto da colaboração farmacêutico-médico nos níveis de pressão arterial. A avaliação foi efetuada por 
comparação com o ponto de partida e entre os dois grupos.
Resultados: Integraram o programa de acompanhamento farmacoterapêutico, 17 hipertensos, 12 do género 
feminino com idade média de 68,50±3,26 e um consumo médio de medicamentos de 6,06±0,93. Do total, 13 
não estavam controlados. Comparando com o início, o grupo de intervenção reduziu, em média, 28,85±5,90 
mmHg (p < 0,0005) na pressão arterial sistólica e 11,23±2,75 mmHg (p < 0,005) na diastólica. Na comparação 
entre grupos, registou-se uma redução de 18,63±6,44 mmHg (p = 0,011) na pressão arterial sistólica e de 
9,03±2,63 mmHg (p < 0,005) na diastólica.
Conclusão: A colaboração farmacêutico-médico em doentes hipertensos numa unidade de saúde familiar 
Portuguesa acrescentou mais-valia clínica aos cuidados de saúde habitualmente recebidos pelos doentes.
Palavras-chave: Assistência Farmacêutica;  Farmacêuticos; Hipertensão; Médicos; Portugal; Pressão 
Sanguínea; Relações Interprofissionais; Resultado do Tratamento; Saúde Familiar  
Introduction 
Improving patients’ health and quality of life is the 
main objective of all health care professionals. There 
is an extensive body of international literature re-
porting significant health improvements when phar-
macists and physicians cooperate to improve pa-
tients’ health, particularly in the case of hypertensive 
patients.1-3 Moreover, the costs associated with the 
ineffectiveness of medication and safety issues are re-
duced, leading to obvious economic savings for the 
health care system.4-6
Collaborative care between pharmacists and physicians 
has been encouraged by several international institu-
tions, including the World Health Organization (Dec-
laration of Alma-Ata),7 the International Federation 
of Pharmacists8,9 and the World Medical Associa-
tion.10
In Portugal, although such interprofessional collabo-
ration at the primary health care level is not wide-
spread, there have been some short-term studies on 
the issue.11-16
The literature in this regard highlights several key 
factors that affect collaborative care, including trust, 
a clear role specification for each professional and the 
standard of professional interaction.17,18
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Pharmaceutical care refers to the pharmacist’s con-
tribution to the care of individuals, which is intended 
to optimise medicine use and improve health out-
comes.19 It is expected that the implementation of a 
pharmaceutical care programme within a Portuguese 
primary health care institution would promote a 
close professional relationship between the pharma-
cist and the physicians, as well as a clear role speci-
fication for these professionals, thereby contributing 
to additional positive clinical outcomes.
The aim of this report is therefore to underline the 
clinical added value for hypertensive patients that re-
sults from a close collaboration between physicians 
and a pharmacist in a Portuguese family health unit.
Methods
Between January 2010 and August 2011, a commu-
nity trial was conducted by a pharmacist at a family 
health unit in Évora, Portugal. Those patients includ-
ed in the intervention group were enrolled in a phar-
maceutical care programme in addition to receiving 
typical physician care. The comparison patients only 
received the typical physician care.
The intervention group were randomly selected from 
the clinical records of the family health unit (i.e., the 
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physician. The patient’s frequency of pharmaceutical 
consultations was defined based on perceived health 
needs and health problems evolution.
For each uncontrolled patient, a strategic interven-
tion plan was designed. During the subsequent con-
sultations (each approximately 30 minutes in dura-
tion), therapeutic goals and suggested interventions 
were discussed with and approved by the patient. The 
pharmacist interventions were adjusted based on the 
clinical evolution. When related to a healthy lifestyle, 
medication adherence or correct drug intake, the inter-
ventions were directed towards the patients, but when 
a medical evaluation and the prescription of medicinal 
products for untreated health problems or changes in 
the therapeutic scheme already prescribed due to inef-
fectiveness or safety issues (dosage, drug replacement, 
new drug) were required, the pharmacist interventions 
were directed towards the physician (family physician 
or other).
In general, in addition to the pharmacist’s verbal expla-
nation, all the interventions were written down so as to 
minimise message distortion and allow for traceability. 
When directed towards the family physician, previous 
contacts to discuss the case were ensured. Despite the 
pharmacist having interacted with all the family physi-
cians whenever necessary (i.e., due to negative clinical 
outcomes in their patients) during the study period, 
monthly appointments with the facilitator physician 
were arranged in order to analyse the project’s evolu-
tion and discuss complex clinical cases. The facilitator 
physician informed all colleagues about the progress of 
the study every six months. 
The detailed knowledge about the study and its prog-
ress, the frequent professional interactions (in the 
same physical structure, personal contacts) and the 
clear role specification for the pharmacist in the fam-
ily health unit were the tools used to build a close and 
trusting relationship with the physicians. 
Among the numerous health problems recorded for all 
the intervention patients, hypertension was the prob-
lem for which the most pharmaceutical interventions 
were addressed to the physician along with a discus-
sion of each clinical case (close collaborative care be-
tween pharmacist and physician). That is why, in the 
present article, we report only the results for the hyper-
tensive patients by way of an example of collaborative 
care.
The blood pressure levels of the intervention group 
were registered in the pharmacist’s records. For the 
comparison patients, the facilitator physician collected 
similar data from the physician’s records. 
selection was not based on any specific disease). The in-
clusion criteria were: being aged over 18 years, the avail-
ability of telephone contact (due to logistical issues) 
and the ability to autonomously visit the family health 
unit. The exclusion criteria were: a cognitive disability 
diagnosed by a physician (e.g., Alzheimer’s disease), be-
ing bedridden and having a family relationship with any 
of the health unit’s care professionals.
In the present article, we only report the results of those 
patients diagnosed by a physician as having arterial hy-
pertension. 
The patients randomised to the intervention group 
(provided they met the inclusion criteria) were invited 
to participate in the pharmaceutical care programme via 
telephone contact made by the pharmacist. A maximum 
of three attempts was made to contact each patient. 
Due to the high dispersion of diseases in the patients 
belonging to the intervention group (selected from 
the global clinical records), comparison patients were 
only selected at the end of the study, matching essential 
characteristics: general practitioner, gender, age group 
and diagnosed diseases. A list of possible comparison 
patients with the relevant characteristics was generated 
for each intervention patient using the physician’s soft-
ware. The respective comparator was the first on the list 
who exhibited the most matching characteristics.
A family physician – referred to as the facilitator phy-
sician – was appointed to follow the entire study and 
to provide the requested information from the clinical 
records, since the pharmacist cannot access the physi-
cian’s records due to ethics issues.
Pharmacist intervention
The pharmaceutical consultations were carried out in 
a private office (independently from the family physi-
cian consultation) and they took place for 4 hours ev-
ery week over the course of 19 months. The service was 
provided through a patient-centred strategy using logi-
cal and methodological reasoning (based on Dáder’s 
method20), as well as specific skills, to detect, prevent 
and solve negative clinical outcomes.
During the first consultation (60 minutes in dura-
tion), the pharmacist recorded the patient’s sociode-
mographic data, personal and family disease history, 
clinical and pharmacotherapeutic history, lifestyle 
and allergies. All the health problems were classified 
according to the ICPC-2 classification scheme.21 The 
achievement of therapeutic goals (based on specific 
guidelines) was assessed through the measurement of 
health parameters during the consultation or through 




The added value for blood pressure control that re-
sulted from the collaborative care intervention was 
assessed by comparing the blood pressure levels be-
tween the intervention and comparison groups (all 
hypertensive patients). For the intervention patients, 
a comparison of the blood pressure levels after fol-
low-up with those at baseline (uncontrolled patients 
only) was also performed.
Procedures for blood pressure measurement 
and devices
The patients’ blood pressure levels were assessed 
with a Tensoval Duo Control™ device. After a five-
minute rest in the correct position and using the cor-
rect cuff size, three measurements were taken in the 
non-dominant arm and the mean value was recorded. 
The therapeutic goals and different hypertension 
grades were based on European guidelines for the 
management of hypertension.22,23
Statistical analysis
The statistical data analysis was performed using a 
two-tailed Student’s t-test for paired comparisons. 
Significance levels of  p = 0.05 were used. The con-
tinuous variables were expressed as the mean ± the 
standard error of the mean.
Ethical considerations
The regional health administration and the fam-
ily health unit’s physicians discussed and accepted 
the project. The National Commission for Data 
Protection also authorised the collection of the pa-
tients’ data. All patients who agree to participate in 
the study signed an informed consent form.
Results
From the initial random list of 400 persons, a total of 39 
patients accepted the pharmacist’s invitation to partici-
pate in the pharmaceutical care programme and signed 
the informed consent form. Seventeen patients had hy-
pertension and hence were analysed. Fig. 1 illustrates 
the flow of patient enrolment in the study. 
Of the 17 hypertensive patients who were analysed 
(Table 1), 12 were female. The mean age was 68.50±3.26 
years, and the most common educational level was 
the compulsory 1st to 9th year education (11 patients). 
Regarding cardiovascular events, a personal history of 
stroke and myocardial infarction was registered for one 
and two patients, respectively, while six patients had 
a family history of stroke. In addition to hypertension, 
Randomized selection 
from the global clinical 
records (n=400) 
Eligible persons  (n=337) 
Persons invited to 
participate in the study 
(n=123) 
63 persons unmet the inclusion criteria 
Selected Comparison 
group (n=29) 
Comparison patients  
(n=17) 
Persons accepted to 
participate in the study 
(n=67) 
214 persons impossible to contact 
by telephone 
56 persons refused to participate 
Grounds for refusal 
- Study with no interest (n=15) 
- Working time incompatibility (n=10) 
- Absence of the city (n=10) 
- No specific reason (n=8) 
- Transport difficulties (n=7) 
- No time available (n=6) 
Persons attended to the 
first consultation (n=39) 
Patients with 
pharmaceutical care need 
(n=34) 
5 persons have no need for 
pharmaceutical care  




with hypertension (n=17) 
5 persons not accepted to receive regular 
pharmaceutical care consultations 
Figure 1. Flow of patient enrolement in the study.
    
hypercholesterolemia (11 patients), overweightness (11 
patients), depression (six patients) and anxiety (five 
patients) were the most common health problems ob-
served. Only one patient was smoker. On average, each 
patient had prescribed 6.06±0.93 medicinal products.
Table 1 describes the baseline characteristics of the 
intervention patients with hypertension and their re-
spective comparators.
According to the blood pressure assessment, 13 inter-
vention patients exhibited uncontrolled levels (blood 
pressure higher than 140/90 mmHg23). For these pa-
tients, 21 pharmacist interventions were performed. 
The family physicians received nine of them and ac-
cepted eight. Additionally, in the case of five phar-
macological interventions addressed to the patient 
(medication adherence and correct drug intake), 
the situation was previously reported and discussed 
with the respective family physician.

























Number of medicinal products
Number of health problems
Mean blood pressure levels
Table 1. Baseline characteristics of the intervention and 
comparison groups
    Intervention 
group































































n.a. – Not available from clinical records.
The pharmacist interventions intended to control the 
patients’ blood pressure levels are presented in Table 2. 
Compared with the baseline (only hypertensive un-
controlled patients, n = 13), statistically significant 
improvements were achieved in the blood pressure 
levels after follow-up. Mean reductions of 28.85±5.90 
mmHg (from 157.46±5.29 to 128.62±3.34 mmHg; p < 
0.0005) in the systolic blood pressure and 11.23±2.75 
mmHg (from 87.08±4.52 to 75.85±3.9 mmHg; p < 
0.005) in the diastolic blood pressure were observed. 
The pharmacist-physician team controlled 11 of the 
13 initially uncontrolled patients, thereby achieving 
the respective therapeutic goals. Regard-
ing the stages of hypertension, of the sev-
en patients with grade 1 hypertension at 
baseline, five improved to exhibit blood 
pressure levels lower than 140 mmHg 
after follow-up, while two remained un-
changed. All the patients with grade 2 and 
grade 3 hypertension (four and two pa-
tients, respectively) at baseline achieved 
their therapeutic goals after follow-up.
A comparison of the clinical achievements 
for the hypertensive patients between the 
intervention group and their comparators 
(all hypertensive patients, whether their 
blood pressure was controlled or not, n 
= 17) showed that collaborative care con-
tributed to statistically significant mean 
reductions in both systolic and diastolic 
blood pressure (p < 0.005 and p = 0.043, re-
spectively). On average, the patients who 
received additional pharmaceutical care 
showed reductions in their systolic blood 
pressure of 22.94±6.17 mmHg (from 
150.25±6.16 to 127.31±3.14 mmHg) and re-
ductions in their diastolic blood pressure 
of 7.56±3.41 mmHg (from 82.31±4.63 to 
74.75±3.26 mmHg). The comparison pa-
tients (those who did not receive pharma-
ceutical care) showed a mean reduction in 
their systolic blood pressure of 4.31±4.46 
mmHg (from 149.80±3.93 to 145.49±5.59 
mmHg), which was not statistically sig-
nificance (p = 0.349), and an average in-
crease in their diastolic blood pressure 
of 1.47±2.82 mmHg, which was again not 
statistically significance (p = 0.608). The 
difference between the groups showed 
that the added value of the pharmacist- 
-physician collaboration in the treatment 
of hypertension was significant, since this collabora-
tion resulted in reductions of 18.63±6.44 mmHg (p = 
0.011) in the systolic blood pressure and 9.03±2.63 
mmHg (p < 0.005) in the diastolic blood pressure. 
Table 3 shows the evolution of the blood pressure 
levels between the intervention group and the com-
parison group. 
The therapeutic goals were achieved for 11 of the 13 
initially uncontrolled patients under pharmaceutical 
care and for eight of the 13 patients in the comparison 
group.
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Discussion
Our results underline the positive impact of pharmacist-
physician collaboration in the treatment of hyperten-
sive patients, which has previously been shown in the 




Medical prescription for untreated hypertension
Addition of a new drug to therapeutic scheme
Medication adherence








Table 2 - Pharmacist interventions made in blood 
pressure levels (n = 13)


























contribution may encourage community pharmacists 
and physicians to collaborate in health care teams. It also 
suggests the need for the permanent inclusion of phar-
macists in family health units in order to ensure that the 
benefits for patients are maintained.26 
The relatively small number of patients involved in the 
study limits the conclusions that can be derived from the 
results. This small number of patients was mainly due to 
the low rate of patient acceptance (Fig. 1) of a new and 
previously unknown service provided by a pharmacist, 
since pharmacists are not usually involved in family he-
alth units. 
The blood pressure improvements observed in our stu-
dy (18.63±6.44 mmHg in systolic blood pressure and 
9.03±2.63 mmHg in diastolic blood pressure) were hi-
gher than those observed in several prior studies (re-
ductions of between 6 and 9 mmHg in systolic blood 
pressure and between 1 and 5 mmHg in diastolic blood 
pressure for patients in receipt of a pharmacist inter-
vention in addition to typical physician care have been 
reported2,3,15,27,28). Apart from the sample size, several 
other factors may have contributed to these differences. 
For instance, different follow-up periods and different 
kinds of pharmaceutical services (not all of them consis-
tent with pharmaceutical care as defined in this article) 
were used in other studies. The frequency of the phar-
maceutical consultations in the present study may also 
have affected the results. In our study, each hypertensive 
patient was followed, on average, for 12.9 months (51.5 
weeks) and received 11.6 pharmaceutical consultations, 
that is, one consultation every four weeks. In previous 
studies, the interval between consultations was higher, 
at between five and 12 weeks.2,3,15,28 It is plausible that 
the higher frequency of pharmaceutical consultations in 
our study allowed for more frequent reinforcement of the 
interventions, resulting in greater reductions in patients’ 
blood pressure levels. Indeed, in a study in which a si-
milar service was implemented and the pharmaceutical 
appointments were also monthly, the authors achieved a 
systolic blood pressure reduction of 18 mmHg.14
The implementation of a pharmaceutical care service 
within a family health unit brings professionals into 
physical proximity and thereby facilitates their interac-
tions. The mutual respect between the physicians and 
the pharmacist, the positive results and the frequent in-
teractions may have improved the pharmacist-physician 
collaboration and, hence, accounted for the higher rate 
of acceptance of the interventions referred to the physi-
cian (eight out of nine). 
An increase of about 30% (p < 0.005) in the hypertension 
control of patients who received pharmacist-physician 
Table 3. Evolution of the blood pressure levels
Mean values, differences and respective statistical 
significance at the beginning of the study and after 
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collaborative care was observed in this study, which 
suggests that this collaboration has the potential to 
improve patients’ health. This result is similar to the 
findings of a study conducted in 2008 by Carter et al 
in which the patients also showed improvements in 
blood pressure control: 89.1% of patients in the in-
tervention group were controlled versus 52.9% in the 
control group.3 Other studies have reported lower 
values of blood pressure control, ranging between 
15% and 18% .2,29 
The added value of pharmacist-physician 
collaborative care for cardiovascular risk 
reduction
Considering a linear relationship between cardio-
vascular risk and blood pressure levels, Houle et 
al30 estimated that for every 5.7 mmHg reduction 
in systolic blood pressure, the overall absolute risk 
of stroke and myocardial infarction will decrease 
by 2.4% and 2%, respectively. Based on this estima-
tion, and considering the reduction of 18.63 mmHg 
(p = 0.011) in systolic blood pressure that was achie-
ved in this study, the overall absolute risk of stroke 
and myocardial infarction in patients under collabo-
rative care will decrease by approximately 7.8% and 
6.5%, respectively.
Based on the interventions performed to control pa-
tients’ blood pressure levels, as well as the clinical 
outcomes achieved (a reduction of 18.63 mmHg in 
systolic blood pressure), the mean added value of a 
pharmacist intervention for hypertensive patients 
was estimated. On average, 1.62 pharmacist inter-
ventions were performed per uncontrolled patient. 
According to the mean reduction achieved in the 
systolic blood pressure, one pharmacist intervention 
corresponded to a reduction of 11.5 mmHg in the sys-
tolic blood pressure. Applying the data from Houle et 
al study, 30 on average, one pharmacist intervention 
provided to hypertensive patients could correspond 
to a 4.8% reduction in the overall absolute risk of 
stroke and a 4% reduction in the overall risk of myo-
cardial infarction.
Conclusion
Within the context of a Portuguese family health 
unit, a close pharmacist-physician collaboration 
adds significant clinical value to the typical care pro-
vided for hypertensive patients. The mean additional 
reductions in blood pressure observed in the uncon-
trolled patients may decrease the risk of future car-
diovascular disease.
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